bm-navigation: bm-t1-home-navigation-1
bm-pageheader: bm-t2-aboutus-pageheader


09.30.21 - Press Releases

HiberCell Appoints Jonathan Lanfear as COO

Expands Board of Directors with Appointment of Cindy Jacobs, PhD, MD NEW YORK, September 30, 2021—HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, today announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach. Mr. Lanfear is an … Continued
Read More
09.08.21 - Press Releases

HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FU

HC-5404-FU PERKi Program is Currently in a Phase 1a Clinical Trial for the Treatment of Solid Tumors NEW YORK, September 8, 2021—HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for HC-5404-FU, an … Continued
Read More
08.16.21 - Press Releases

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.  Deal strengthens HiberCell’s balance sheet, accelerates clinical programs and expands pre-clinical pipeline through the integration of next generation artificial intelligence (AI) and machine learning (ML) strategies     NEW YORK and BOSTON, August 16, 2021—HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer … Continued
Read More
06.29.21 - Press Releases

HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific Officer

Industry veteran promoted to oversee discovery of HiberCell’s scientific pipeline New York, NY, June 29, 2021—HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with … Continued
Read More
06.10.21 - Press Releases

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the initiation of a Phase 1a multicenter, open-label, dose escalation trial of its orally administered HC-5404-FU in patients with selected metastatic solid tumors. HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.
Read More
05.19.21 - Press Releases

HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital

Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis   NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) — HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced that it has completed a Series B financing round for gross proceeds of $67.4 million.   Concurrent … Continued
Read More
01.21.21 - Press Releases

HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D.

HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointments of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D., to its scientific advisory board. “We’re thrilled to welcome such distinguished scientists to our advisory board,” said Alan C. Rigby, Ph.D., co-founder and chief executive officer of HiberCell.
Read More
01.13.21 - Press Releases

HiberCell and Biodesix Initiate Broad Collaboration forCompanion Diagnostic Discovery, Development and Commercialization

HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc. (Nasdaq: BDSX) to further the development of an enzyme-linked immunosorbent assay (ELISA) as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs. Terms of the partnership were not disclosed.
Read More
12.02.20 - Press Releases

HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer

HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.
Read More
07.07.20 - Press Releases

HiberCell Announces Acquisition of Biothera Pharmaceuticals’ Imprime PGG Program

HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced the acquisition of Biothera Pharmaceuticals' (Biothera) Imprime PGG program. HiberCell will integrate Biothera's Minnesota-based staff, operations and other assets into the company.
Read More
12.04.19 - Media - Nature

Nature Sponsored Feature – Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasis

The field of cancer therapy is an area of intense investment that is driving drug discovery and development. This burgeoning area of research and development has yielded tremendous scientific advances.
Read More
08.06.19 - Press Releases

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors

HiberCell announced the appointment of Colin Goddard to the company's Board of Directors. The company also announced that Steven Gillis will assume the role of Chairman.
Read More
02.07.19 - Media - STAT

STAT – New York biotech debuts, targeting dormant metastatic cancer cells

A biotech based on the frightening fact that some cancer cells spread throughout the body even before a tumor is detectable emerged from stealth mode on Thursday, announcing it had raised roughly $60 million from, among others, early-stage venture capital companies and one of biotech’s 800-pound gorillas. Read full story by Sharon Begley here.
Read More
02.07.19 - Media - FierceBiotech

FierceBiotech – Biotech HiberCell launches with $60M+ to combat cancer relapse and metastasis

HiberCell, a new startup focused on preventing cancer metastasis and relapse, launched Thursday with research out of Mount Sinai and $60.75 million from the likes of ARCH Venture Partners, Hillhouse Capital and 6 Dimensions Capital. Read full story by Amirah Al Idrus here.
Read More
02.07.19 - Media - Endpoints

Endpoints – Arch joins Celgene, China investors bankrolling a pioneering New York biotech startup focused on a new approach to metastasis

Julio Aguirre-Ghiso has steered the work in his lab at Mount Sinai down some of the less-traveled pathways of cancer research. And it’s led him to launch a biotech — which is having its coming-out party today in New York — that has now set out to develop new medicines tailored for the field he’s … Continued
Read More
02.07.19 - Press Releases

HiberCell Launches to Prevent Cancer Relapse and Metastasis with Novel Therapeutics

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series A funding led by ARCH Venture Partners. HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics.
Read More
Load More

Presentations & Publications

04.14.20 - Adaptive Stress Modulators

The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling

Authors: Eslam Mohamed, Rosa A. Sierra Jimena Trillo-Tinoco, Yu Cao Patrick Innamarato, Kyle K. Payne Alvaro de Mingo Pulido, Jessica Mandula Shuzhong Zhang, Paul Thevenot Subir Biswas, Sarah K. Abdalla, Tara Lee Costich Kay Hänggi, Carmen M. Anadon, Elsa R. Flores, Eric B. Haura, Shikhar Mehrotra, Shari Pilon-Thomas, Brian Ruffell, David H. Munn, Juan R. Cubillos-Ruiz, Jose R. Conejo-Garcia, Paulo C. Rodriguez
Article Immunity
04.01.20 - Microenvironment Modulator

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Presented at the 2020 AACR Virtual Annual Meeting. Authors: O’Day SJ, Borges, VF, Chmielowski B, et al.
Article ASCO Post
03.13.20 - Adaptive Stress Modulators

Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia

Authors: Sylwia Bartoszewska & James F. Collawn
Article Cellular & Molecular Biology Letters
03.04.20 - Microenvironment Modulator

Defining trained immunity and its role in health and disease

Authors: Mihai G. Netea, Jorge Domínguez-Andrés, Luis B. Barreiro, Triantafyllos Chavakis, Maziar Divangahi, Elaine Fuchs, Leo A. B. Joosten, Jos W. M. van der Meer, Musa M. Mhlanga, Willem J. M. Mulder, Niels P. Riksen, Andreas Schlitzer, Joachim L. Schultze, Christine Stabell Benn, Joseph C. Sun, Ramnik J. Xavier & Eicke Latz
Article Nature Reviews Immunology
12.01.19 - Microenvironment Modulator

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Presented at San Antonio Breast Cancer Conference. Authors: Uhlik M., Bose N., Cox J., Mattson P., Gargano M., O'Day S., Borges V., Chmielowski B., Rao R., Abu-Khalaf M., Stopeck A., Chisamore M., Osterwalder B., Graff J.
11.01.19 - Microenvironment Modulator

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy

Presented at 2019 SITC Annual Conference. Authors: Nadine R. Ottoson, Anissa SH Chan, Xiaohong Qiu, Ben Harrison, Richard Walsh, Paulette Mattson, Michele Gargano, Joanna Cox, Michael Chisamore, Mark Uhlik, Jeremy R. Graff, and Nandita Bose
11.01.19 - Microenvironment Modulator

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

Presented at 2019 SITC Annual Conference. Authors: Anissa SH Chan, Nadine R. Ottoson, XiaohongQiu, Ben Harrison, Richard Walsh, Paulette Mattson, Michele Gargano, Joanna Cox, Michael Chisamore, Mark Uhlik, Jeremy R. Graff, and Nandita Bose. 
10.01.19 - Dormancy & Metastasis

Tumor Dormancy and Slow-Cycling Cancer Cells

Authors: John E. Davis Jr., Jason Kirk, Yibing Ji, Dean G. Tang
Article Advances in Experimental Medicine and Biology
09.01.19 - Dormancy & Metastasis

Tumor Dormancy and Interplay with Hypoxic Tumor Microenvironment

Authors: Elena Butturini, Alessandra Carcereri de Prati, Diana Boriero, Sofia Mariotto
Article International Journal of Molecular Sciences
05.01.19 - Microenvironment Modulator

β-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1

Authors: Simone J.C.F.M. Moorlag, Nargis Khan, Boris Novakovic, Eva Kaufmann, Trees Jansen, Reinout van Crevel, Maziar Divangahi, Mihai G. Netea
Article Cell Reports
05.01.19 - Microenvironment Modulator

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Authors: Nandita Bose, Nadine R. Ottoson, Xiaohong Qiu, Ben Harrison, Jamie R. Lowe, Mark T. Uhlik, Blaine T. Rathmann, Takashi O. Kangas, Lindsay R. Jordan, Kathleen E. Ertelt, Adria Bykowski Jonas, Richard M. Walsh, Anissa S. H. Chan, Ross B. Fulton, Steven M. Leonardo, Kathryn A. Fraser, Keith B. Gorden, Mark A. Matson, Jeremy R. Graff and Richard D. Huhn
Article The Journal of Immunology
05.01.19 - Adaptive Stress Modulators

Unfolded Protein Response (UPR) in Survival, Dormancy, Immunosuppression, Metastasis, and Treatments of Cancer Cells

Authors: Sheng-Kai Hsu, Chien-Chih Chiu, Hans-Uwe Dahms, Chon-Kit Chou, Chih-Mei Cheng, Wen-Tsan Chang, Kai-Chun Cheng, Hui-Min David Wang, I-Ling Lin
Article International Journal of Molecular Sciences
04.01.19 - Microenvironment Modulator

Therapeutic targeting of trained immunity

Authors: Willem J. M. Mulder, Jordi Ochando, Leo A. B. Joosten, Zahi A. Fayad & Mihai G. Netea
Article Nature Reviews Drug Discovery
03.01.19 - Adaptive Stress Modulators

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

Authors: Yu Cao, Jimena Trillo-Tinoco, Rosa A. Sierra, Carmen Anadon, Wenjie Dai, Eslam Mohamed, Ling Cen, Tara L. Costich, Anthony Magliocco, Douglas Marchion, Richard Klar, Sven Michel, Frank Jaschinski, Richard R. Reich, Shikhar Mehrotra, Juan R. Cubillos-Ruiz, David H. Munn, Jose R. Conejo-Garcia & Paulo C. Rodriguez
Article Nature Communications
02.01.19 - Dormancy & Metastasis

Dormancy in cancer

Authors: Hiroko Endo, Masahiro Inoue
Article Cancer Science
01.01.19 - Dormancy & Metastasis

Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting

Authors: Sarmistha Talukdar, Praveen Bhoopathi, Luni Emdad, Swadesh Das, Devanand Sarkar, Paul B Fisher
Article Advacnced Cancer Research
01.01.19 - Dormancy & Metastasis

Targeting Cancer Cell Dormancy

Authors: Ariadna Recasens, Lenka Munoz
Article Trends in Pharmacology Science
10.01.18 - Dormancy & Metastasis

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Authors: Elin Borgen, Maria C. Rypdal, Maria Soledad Sosa, Anne Renolen, Ellen Schlichting, Per E. Lønning, Marit Synnestvedt, Julio A. Aguirre-Ghiso & Bjørn Naume
Article Breast Cancer Research
09.01.18 - Dormancy & Metastasis

How dormant cancer persists and reawakens

Author: Julio A Aguirre-Ghiso
Article Science
06.01.18 - Adaptive Stress Modulators

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases

Authors: Arnaud Pommier, Naishitha Anaparthy, Nicoletta Memos, Z. Larkin Kelley, Alizée Gouronnec, Ran Yan, VCédric Auffray, Jean Albrengues, Mikala Egeblad, Christine A. Iacobuzio-Donahue, Scott K. Lyons, Douglas T. Fearon
Article Science
05.01.18 - Adaptive Stress Modulators

Development of a stress response therapy targeting aggressive prostate cancer

Authors: Hao G Nguyen , Crystal S Conn, Yae Kye, Lingru Xue, Craig M Forester, Janet E Cowan, Andrew C Hsieh, John T Cunningham, Charles Truillet, Feven Tameire, Michael J Evans, Christopher P Evans, Joy C Yang, Byron Hann, Constantinos Koumenis, Peter Walter, Peter R Carroll, Davide Ruggero
Article Science Translational Medicine
04.01.18 - Microenvironment Modulator

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

American Association for Cancer Research Annual Meeting. Authors: Mingen Liu, Kathleen Graham, Anissa SH. Chan, Nadine R. Ottoson, Nandita Bose, Gregory L. Beatty
04.01.18 - Microenvironment Modulator

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

American Association for Cancer Research Annual Meeting. Authors: Kathryn Fraser, Nadine Ottoson, Xiahong Qiu, Anissa SH Chan, Adria Jonas, Takashi Kangas, Jeremy Graff, Nandita Bose
04.01.18 - Microenvironment Modulator

Imprime PGG, a soluble yest β-glucan PAMP, enhancement of anit-tumor responses in comination with tumor targeting antibody is highly dependent on NK cell killing

American Association for Cancer Research Annual Meeting. Authors: Kathryn A. Fraser, Takashi Kangas, Ross B. Fulton, Steven M. Leonardo, Ben Harrison, Yumi Yokoyama, Nandita Bose, Jeremy R. Graff, Mark Uhlik, and Keith B. Gorden
03.01.18 - Adaptive Stress Modulators

The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma

Authors: Peter Makhov, Sei Naito, Miki Haifler, Alexander Kutikov, Yanis Boumber, Robert G. Uzzo & Vladimir M. Kolenko
Article Cell Death & Disease
02.01.18 - Microenvironment Modulator

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Authors: Walburga Engel-Riedel 1, Jamie Lowe 2, Paulette Mattson 2, J Richard Trout 3, Richard D Huhn 2, Michele Gargano 2, Myra L Patchen 4 5, Richard Walsh 2, My My Trinh 6, Mariève Dupuis 6, Folker Schneller 7
Article Journal for ImmunoTherapy of Cancer
01.01.18 - Dormancy & Metastasis

Role of HIF-1 in Cancer Progression: Novel Insights. A Review

Authors: Aldo Pezzuto, Elisabetta Carico
Article Current Molecular Medicine
01.01.18 - Microenvironment Modulator

Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity

Authors: Ioannis Mitroulis, Klara Ruppova, Baomei Wang, Lan-Sun Chen, Michal Grzybek, Tatyana Grinenko, Anne Eugster, Maria Troullinaki, Alessandra Palladini, Ioannis Kourtzelis, Antonios Chatzigeorgiou, Andreas Schlitzer, Marc Beyer, Leo A.B. Joosten, Berend Isermann, Mathias Lesche, Andreas Petzold, Kai Simons, Ian Henry, Andreas Dahl, Joachim L. Schultze, Ben Wielockx, Nicola Zamboni, Peter Mirtschink, Ünal Coskun, George Hajishengallis, Mihai G. Netea, Triantafyllos Chavakis
Article Cell
10.01.17 - Adaptive Stress Modulators

Cancer-specific PERK signaling drives invasion and metastasis through CREB3L

Authors: Yu-Xiong Feng, Dexter X. Jin, Ethan S. Sokol, Ferenc Reinhardt, Daniel H. Miller & Piyush B. Gupta
Article Nature Communications
01.01.17 - Dormancy & Metastasis

Circulating and disseminated tumor cells: harbingers or initiators of metastasis?

Authors: Arko Dasgupta Andrea R. Lim Cyrus M. Ghajar
Article Molecular Oncology
12.01.16 - Dormancy & Metastasis

Mechanism of early dissemination and metastasis in Her2 + mammary cancer

Authors: Kathryn L. Harper, Maria Soledad Sosa, David Entenberg, Hedayatollah Hosseini, Julie F. Cheung, Rita Nobre, Alvaro Avivar-Valderas, Chandandaneep Nagi, Nomeda Girnius, Roger J. Davis, Eduardo F. Farias, John Condeelis, Christoph A. Klein & Julio A. Aguirre-Ghiso
Article Nature
11.01.16 - Microenvironment Modulator

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Authors: Anissa S. H. Chan ,Adria Bykowski Jonas ,Xiaohong Qiu,Nadine R. Ottoson,Richard M. Walsh,Keith B Gorden,Ben Harrison,Peter J. Maimonis,Steven M. Leonardo,Kathleen E. Ertelt,Michael E. Danielson,Kyle S. Michel,Mariana Nelson,Jeremy R. Graff,Myra L. Patchen,Nandita Bose
Article PLOS One
01.01.16 - Adaptive Stress Modulators

The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress

Authors: W Rozpedek, D Pytel, B Mucha, H Leszczynska, J A Diehl, I Majsterek
Article Current Molecular Medicine
08.01.15 - Adaptive Stress Modulators

Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy

Authors: Feven Tameire, Ioannis I Verginadis, Constantinos Koumenis
Article Seminars in Cancer Biology
01.01.15 - Dormancy & Metastasis

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

Authors: Maria Soledad Sosa, Falguni Parikh, Alexandre Gaspar Maia, Yeriel Estrada, Almudena Bosch, Paloma Bragado, Esther Ekpin, Ajish George, Yang Zheng, Hung-Ming Lam, Colm Morrissey, Chi-Yeh Chung, Eduardo F. Farias, Emily Bernstein & Julio A. Aguirre-Ghiso
Article Nature Communications
08.01.14 - Dormancy & Metastasis

Mechanisms of disseminated cancer cell dormancy: an awakening field

Authors: María Soledad Sosa, Paloma Bragado & Julio A. Aguirre-Ghiso
Article Nature Reviews Cancer
04.01.14 - Microenvironment Modulator

Differential regulation of oxidative burst by distinct beta-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells

Authors: Nandita Bose 1, Lindsay R Wurst, Anissa S H Chan, Christine M Dudney, Megan L LeRoux, Michael E Danielson, Paul M Will, Sonja E Nodland, Myra L Patchen, Jurandir J Dalle Lucca, Frank J Lebeda, John P Vasilakos
Article Glycobiology
11.01.13 - Dormancy & Metastasis

Mechanisms governing metastatic dormancy and reactivation

Author: Filippo G Giancotti
Article Cell
10.01.13 - Dormancy & Metastasis

TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling

Authors: Paloma Bragado, Yeriel Estrada, Falguni Parikh, Sarah Krause, Carla Capobianco, Hernan G. Farina, Denis M. Schewe & Julio A. Aguirre-Ghiso
Article Nature Cell Biology
08.01.13 - Microenvironment Modulator

Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent

Authors: Nandita Bose, Anissa S. H. Chan, Faimola Guerrero, Carolyn M. Maristany, Xiaohong Qiu, Richard M. Walsh, Kathleen E. Ertelt, Adria Bykowski Jonas, Keith B. Gorden, Christine M. Dudney, Lindsay R. Wurst, Michael E. Danielson, Natalie Elmasry, Andrew S. Magee, Myra L. Patchen and John P. Vasilakos
Article Frontiers in Immunology
03.01.13 - Adaptive Stress Modulators

PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS

Authors: Kasper M. Rouschop, Ludwig J. Dubois, Tom G. Keulers, Twan van den Beucken, Philippe Lambin, Johan Bussink, Albert J. van der Kogel, Marianne Koritzinsky, and Bradly G. Wouters
Article PNAS
11.01.12 - Adaptive Stress Modulators

ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth

Authors: Lori S. Hart, John T. Cunningham, Tatini Datta, Souvik Dey, Feven Tameire, Stacey L. Lehman, Bo Qiu,1 Haiyan Zhang, George Cerniglia, Meixia Bi, Yan Li, Yan Gao, Huayi Liu, Changhong Li, Amit Maity, Andrei Thomas-Tikhonenko, Alexander E. Perl, Albert Koong, Serge Y. Fuchs, J. Alan Diehl, Ian G. Mills, Davide Ruggero, and Constantinos Koumenis
Article Journal of Clinical Investigation
05.01.12 - Adaptive Stress Modulators

PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage

Authors: E Bobrovnikova-Marjon, C Grigoriadou, D Pytel, F Zhang, J Ye, C Koumenis, D Cavener & J A Diehl
Article Oncogene
06.01.11 - Microenvironment Modulator

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans

Authors: Chunjian Qi, Yihua Cai, Lacey Gunn, Chuanlin Ding, Bing Li, Goetz Kloecker, Keqing Qian, John Vasilakos, Shinobu Saijo, Yoichiro Iwakura, John R Yannelli, Jun Yan
Article Blood
04.01.11 - Microenvironment Modulator

Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’

Authors: Helen S. Goodridge, Christopher N. Reyes, Courtney A. Becker, Tamiko R. Katsumoto, Jun Ma, Andrea J. Wolf, Nandita Bose, Anissa S. H. Chan, Andrew S. Magee, Michael E. Danielson, Arthur Weiss, John P. Vasilakos & David M. Underhill
Article Nature
02.01.08 - Microenvironment Modulator

Yeast-Derived β-Glucan Augments the Therapeutic Efficacy Mediated by Anti–Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models

Authors: Carolina Salvador, Bing Li, Richard Hansen, Daniel E. Cramer, Maiying Kong and Jun Yan
Article Clinical Cancer Research
08.01.07 - Microenvironment Modulator

Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55

Authors: Bing Li, Daniel J. Allendorf, Richard Hansen, Jose Marroquin, Daniel E. Cramer, Claire L. Harris and Jun Yan
Article Clinical Cancer Research
08.01.06 - Microenvironment Modulator

Yeast β-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway

Authors: Bing Li, Daniel J. Allendorf, Richard Hansen, Jose Marroquin, Chuanlin Ding, Daniel E. Cramer and Jun Yan
Article The Journal of Immunology
Load More